Introduction
Prostate cancer (PCa) is the second leading cause of male cancer-related deaths in Western populations and is projected to become the most common cancer in men by 2020. 1 PCa is usually an indolent disease, but 25-30% of tumours behave aggressively. 2 Currently, there is no successful long-term cure for metastatic PCa. Furthermore, diagnosis of metastatic PCa by measurement of prostate-specific antigen is prone to significant uncertainty. 3 We showed previously that functional voltage-gated sodium channels (VGSCs) are expressed specifically in strongly metastatic cells of rat 4 and human PCa. 5 VGSC activity has also been shown to enhance several cellular behaviours linked to metastasis, including morphological change, 6 endocytosis/secretory membrane activity, 7 galvanotaxis, 8 invasion, 4, 5, 9 lateral motility 10 and interaction with the substrate. 11 In addition, VGSC expression is upregulated during human PCa progression in vivo. 12 However, the mechanism(s) responsible for (i) the VGSC upregulation and (ii) potentiation of the metastatic cellular behaviours are not known.
The Notch pathway has been shown to play key roles in development and tissue homeostasis, including formation of the prostate gland. 13 Notch signalling is also being increasingly implicated in a range of human neoplasms (reviewed by Allenspach et al. 14 and Radtke and Raj 15 ). Thus, the potential role of Notch signalling in PCa has received some attention recently, 16 including possible effects on metastasis 17, 18 and growth of metastatic PCa cells in bone. 19 A part of metastatic progression of PCa is neuroendocrine (NE) differentiation. 20, 21 This phenomenon is still poorly understood, although recently a number of candidate mediators and biomarkers of NE cells were identified. 22 One such mediator could be the basic helix-loop-helix transcription factor mouse achaete-scute homologue (mASH1), the human orthologue of which (hASH1) has been shown to be highly expressed in human PCa NE cells. 22 mASH1 also interacts with components of the Notch pathway in certain cellular systems [23] [24] [25] and promotes expression of the Notch ligand Delta-like1 (Dll1). 23, 26 Dll1 is best known for its role in cellular differentiation, 27 although it also plays a role in adhesion 28 and has been suggested to be a regulator of cellular motility not involving either Su(H)-dependent Notch signalling 29 or Notch signalling generally. 30 The aims of the present study were to assess the status of Notch pathway activity in human PCa cell lines of differing metastatic potential and to investigate whether Notch signalling (with particular reference to Dll1) could contribute to the motility of these cells. A possible interaction between VGSC expression/activity and the Notch pathway has also been investigated. A summary of the possible relevant pathways is illustrated in Figure 1 .
Materials and methods

Cell lines and tissue culture
Four human prostate cell lines of varying metastatic potential were used for Notch expression profiling: (1) PNT2, a model for normal prostate epithelial cells; [31] [32] [33] (2) LNCaP, a non-metastatic cell line derived from a supraclavicular lymph node from a patient with hormone-refractory PCa; 34 (3) PC-3, a moderately metastatic cell line derived from a bone marrow metastasis of a human prostate adenocarcinoma 35 and (4) PC-3M, a strongly metastatic cell line derived from tumourforming PC-3 cells injected into nude mice. 36 The three PCa cell lines (LNCaP, PC-3 and PC-3M) were grown in Roswell Park Memorial Institute (RPMI) 1640 medium without phenol red (Invitrogen, Paisley, UK), supplemented with 10% foetal bovine serum, 4 mM Lglutamine, 1.5 g/l sodium bicarbonate, 10 mM HEPES and 1 mM sodium pyruvate. PNT2 cells were grown in RPMI 1640 medium supplemented with 10% foetal calf serum and 4 mM L-glutamine. Cells were seeded into 60 or 35 mm Falcon dishes, depending on the experiment, and grown in an incubator at 371C, 100% humidity and 5% CO 2 .
Real-time reverse transcription-polymerase chain reaction
Total RNA was extracted from all four human prostate cell lines using the Absolutely RNA reverse transcription-polymerase chain reaction (RT-PCR) Miniprep kit (Stratagene, La Jolla, CA, USA) and total cDNA prepared from 1 mg RNA using the Superscript First Strand Synthesis for RT-PCR (Invitrogen). TaqMan quantitative RT-PCR analysis was performed (ABI PRISM 7700 Sequence Detection System and software; Applied Biosystems, Foster City, CA, USA) using specific primers and probes for human notch1-4, jagged1-2, Dll1, hes1 and deltex as well as human Na v 1.7, the predominant isoform of VGSC in human PCa cell lines. 37 All primers were synthesized by a commercial source (Assays-on-Demand Gene Expression Products, Applied Biosystems). The specific primers and probes for the control 'housekeeping' genes, human 18S and hprt, were also purchased from a commercial source (18S Pre-Developed Assay Reagent and hprt Gene Expression Assays-onDemand, both from Applied Biosystems). Five experiments were performed using cDNAs generated from five separate RNA extractions and each experiment was performed in triplicate.
ABI PRISM 7700 Sequence Detection System equipment and software (both Applied Biosystems) were used for data analysis. Expression levels of genes of interest were normalized to levels of the housekeeping genes and compared by means of the comparative C T method according to the manufacturer's instructions, using gene expression levels in the PNT2 cell line as the calibrator. The results are presented as average fold changes (AFCs) in relative mRNA levels7s.d. Variations in transcript levels were only considered to be significant if X2.5-fold, compared to levels in the control cell line. 38 
Pharmacology
Inhibition of the endogenous Notch pathway was achieved using two peptidomimetic inhibitors of gsecretase: compound 1 (DFK-167, Enzyme Systems Products) and DAPT (N-[N-(3,5-difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester; Calbiochem, Nottingham, UK). Control dishes were treated with the final concentration of the solvent dimethylsulphoxide (DMSO) (0.01-0.1%) (Sigma, Dorset, UK).
The predominant isoform of the VGSC in human PCa cell lines (Na v 1.7) is blocked by tetrodotoxin (TTX) with an IC 50 of approximately 20 nM.
39 TTX (Sigma) was made as a stock solution (3132 mM) in the culture medium, frozen at À201C, defrosted and diluted as required.
Cellular motility
Cellular motility assays were performed in wound-heal assays, as described previously. 10 Briefly, cells were by Notch eventually leads to the intra-membrane region of the receptor being cleaved by g-secretase, releasing the intra-cellular domain (ICD). The ICD translocates to the nucleus where it binds to the transcription factor CSL, eventually inducing gene transcription (e.g. Hes1) and participation in events important in PCa progression/metastasis (e.g. cell motility). Possible effects of Notch pathway activation on VGSC transcription are indicated. In addition, proposed effects of Notch pathway activation on inhibition of Dll1 expression through a yet to be identified pathway ('X') are also indicated ('À' sign indicates inhibitory pathway). Please note, a role for the Notch ligand Dll1 in cell motility, independent of Notch signalling, has also been proposed. 30 Membrane depolarization can lead to the activation of VGSCs, which can then potentiate several cell behaviours linked to metastasis, including cell motility.
Voltage-gated sodium channels and notch signalling N Scorey et al plated in 35 mm Petri dishes at an initial density of 5 Â 10 5 cells/dish and allowed to settle overnight. Three 'wounds' of 0.5-0.9 mm width were made in each dish using a sterile 200 ml Gilson pipette tip. Fresh medium (with or without a given drug or toxin) was then added to each dish. Wound widths were determined immediately afterwards (0 h) by measuring the width of the wound at 45 fixed points per dish using a graticule on an inverted microscope (Zeiss, ID 03). The same sites were then re-measured after 24 and 48 h, with a change of medium at 24 h. For each condition, three dishes were used per experiment, and this was repeated a minimum of three times, giving at least 405 individual data points for the analysis of each condition.
Data from all repeats were grouped for the initial wound widths (W 0 ). Cellular motility was quantified as the 'motility index' (MI) as follows:
where W t is the width of the wound after 48 h. Thus, MI ¼ 0 would indicate no movement of cells, whereas MI ¼ 1 would indicate complete closure of the wound. Statistical significance was determined with Student's t-test.
Proliferation and toxicity assays
Proliferation and toxicity assays were performed as described previously. 6, 40 Briefly, for proliferation, cells were plated in 35 mm Falcon tissue culture dishes at an initial density of 3 Â 10 4 cells/dish and allowed to settle overnight. Each cell line was then incubated in 0.8 ml normal growth medium with or without the added drug for 48 h, with an identical solution change at 24 h. Proliferation was quantified using the colorimetric 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay. 4 Accordingly, sterile 0.2 ml MTT (5 mg/ml made up in the growth medium) was added to the 0.8 ml of fresh medium in the tissue culture dishes. The plates were then incubated at 371C for 6 h. The medium was then removed and replaced with 1 ml DMSO to lyse the cells. 0.1 ml of each cell lysate solution was then added to 0.9 ml fresh DMSO in a 1.5 ml cuvette, followed by 0.125 ml glycine buffer (pH 10.5). Spectrophotometric absorbance at 570 nm was read 10 min after the addition and mixing of the glycine buffer. Previous determination of the standard curves had indicated that the readings were on the linear portion of the calibration. 4 The possible toxicity of the drugs used was tested on cells set up as described previously for the proliferation assays. Toxicity was quantified using the colorimetric trypan blue assay. A 0.2 ml of 0.5% trypan blue (Sigma) was added to 0.8 ml of fresh medium in the tissue culture dishes. The plates were then incubated at 371C for 10 min. The solution was removed and replaced with fresh medium. Using an inverted microscope, the numbers of live and dead cells were counted in 40 different, randomly chosen, but non-overlapping, fields of view.
Neither g-secretase inhibitor was found to be toxic nor to have an effect on proliferation at 20 mM (not shown). We have shown previously that TTX (p6 mM) is not toxic and does not have an effect on the proliferation of PCa cells. 40 
Results
Notch cascade component expression profiles
Typical expression profiles of the Notch signalling components studied are shown in Figure 2 ; the averaged relative transcript levels are summarized in Table 1 . Overall, the results of the TaqMan RT-PCR analyses showed that the expression patterns of Notch signalling cascade components varied significantly in the three PCa cell lines (LNCaP, PC-3 and PC-3M) when compared to the normal prostate epithelial PNT2 cell line. In addition, significant differences in transcript levels of several components were noted between the non-metastatic and metastatic PCa cells (LNCaP vs PC-3 and PC-3M). Table 1 ) and PC-3M cells (AFC ¼ 3.771.1; Table 1 ), whereas PC-3 cells were not significantly different. In contrast, Notch2 receptor levels showed a significant increase in the PC-3M cells only (AFC ¼ 4.370.3; Table 1 ).
The Notch ligands Jagged1, Jagged2 and Dll1 were expressed in all three PCa cell lines (Figure 2b ). Transcript levels for Jagged1 were significantly higher in all three cell lines with an average increase of over eight-fold relative to the levels in normal prostate cells. Jagged2 expression did not vary significantly among the cell lines studied. Interestingly, Dll1 was highly expressed in LNCaP cells (AFC ¼ 10.171.1; Table 1 ), but was downregulated in both PC-3 and PC-3M cell lines (AFC ¼ 0.0870.01 and 0.170.03, respectively), in comparison to the PNT2 cells.
The Notch downstream target Hes1, but not Deltex, was expressed in all four cell lines. The mRNA levels of Hes1 were significantly lower in the non-metastatic LNCaP cell line (AFC ¼ 0.270.03), whereas the transcript levels of the two metastatic cell lines did not differ from the control cell line or each other (Figure 2c ).
Dll1 expression and cellular motility
The effects of two different blockers of the Notch pathway, the g-secretase inhibitors DAPT and Compound 1 were then tested on Dll1 expression levels in the non-metastatic cell line LNCaP and compared to the moderately metastatic cell line PC-3. Expression levels did not change significantly in LNCaP cells with either inhibitor (not shown). However, significant dose-dependent changes were observed in the PC-3 cell line, as follows. DAPT (at 1 mM) significantly reduced Dll1 mRNA levels, whereas higher concentrations had no significant effect (Figure 3a) . Compound 1 (at 1-10 mM) had no significant effect on Dll1 mRNA levels, but 20 mM raised Dll1 transcript levels more than four-fold above baseline (Figure 3a) .
Treatment conditions that had induced significant changes in Dll1 expression levels were then tested for effects on motility of PC-3 cells. DAPT (1 mM) had no effect at 24 h, but increased motility by 8% after 48 h (Po0.001; Figure 3b ). Compound 1 (20 mM) reduced motility by 19% (24 h) and 38% (48 h) (Po0.001 for both; Figure 3c ).
Dll1 interaction with downstream targets
The possible signalling components of the Notch pathway through which Dll1 could be acting were examined. Thus, the effects of the g-secretase inhibitors were tested on Hes1 expression in LNCaP compared to the PC-3 cell line (Figure 4a and b) . DAPT reduced Hes1 levels in a dose-dependent manner in both cell lines. Thus, the maximal concentration tested (20 mM) reduced Hes1 levels in LNCaP and PC-3 cells by 79 and 74%, respectively (Figure 4a and b) . On the other hand, although Compound 1 has been shown previously to inhibit Notch signalling, 41 under our conditions it was not as effective as DAPT. Thus, maximal reductions of Hes1 expression were 8% for the LNCaP cells (at 20 mM) and 20% at 1 mM for the PC-3 cell line (Figure 4 ).
To test whether (i) Hes1 was involved in cell motility and (ii) Dll1 was acting through Hes1, we used DAPT at a concentration that had induced significant changes in Hes1 (but not Dll1) expression. Thus, at 20 mM, DAPT had no effect on LNCaP cell motility, but significantly reduced motility of PC-3 cells by 20% after 24 h (Po0.001; Figure 5 ). At 48 h, motilities of both LNCaP Voltage-gated sodium channels and notch signalling N Scorey et al and PC-3 cell lines were reduced by 16 and 56%, respectively (Po0.001 for each; Figure 5 ), indicating that Hes1 was also involved in cell motility through a mechanism that did not involve Dll1.
Lack of interaction between Notch cascade components and VGSC
We have shown previously that the VGSC channel blocker TTX significantly reduced motility of PCa cells. 10 We therefore investigated whether Notch pathway components and VGSC activity were linked in their effects on cell motility. First, Nav1.7 mRNA expression levels were monitored for changes induced by 48 h incubation with 1, 5, 10 and 20 mM DAPT. No significant changes in Nav1.7 transcript levels were detected at any concentration of DAPT in PC-3 cells (Figure 6a ). Nav1.7 transcript levels in LNCaP cells were either undetectable or low (not shown). Second, the reverse treatment was tested. Thus, both cell lines were incubated with TTX (1 mM) for 48 h. No significant changes in Hes1 mRNA levels were detected in either LNCaP or PC-3 cell lines (Figure 6b) . A longer term treatment of the same cells with TTX (1 mM) over 72 h also had no effect on Hes1 expression (data not shown). TTX (at 1 mM) had no effect on motility in the LNCaP cell line (not illustrated), but significantly reduced the migration of the PC-3 cell line by 59 and 31% after 24 and 48 h, respectively (Table 2) . However, 1 mM TTX would induce maximal VGSC block in PC-3 cells. 5 In a similar manner, 20 mM DAPT could be a saturating concentration for inhibiting the Notch pathway (Figure 4) . Thus, to Voltage-gated sodium channels and notch signalling N Scorey et al investigate possible interaction of Notch signalling and VGSC activity, effects of TTX and DAPT were tested at the lower concentrations of 5 nM and 5 mM, respectively. At 24 h, there was no effect on motility of TTX (5 nM) by itself, DAPT (5 mM) by itself or TTX (5 nM) þ DAPT (5 mM) (not shown). However, at 48 h, both DAPT (5 mM) and TTX (5 nM) reduced motility significantly by 6 and 10%, respectively (Po0.01 for both; Table 2 ). Importantly, when combined, these two agents reduced migration by 20% (Po0.001; Table 2 ). It was concluded that the effects of TTX and DAPT on motility were additive, that is, likely to be independent.
Discussion
The results of the present study showed (1) that Notch signalling is active in PCa cell lines and could contribute to metastatic cell behaviour (motility), (2) that the Notch ligand Dll1 restricts cell motility, but may not mediate this effect through Notch signalling and (3) that the apparent involvements of Notch signalling and VGSC activity in PCa cell motility are independent. Thus, the functional VGSC upregulation that we reported to occur specifically in metastatic PCa 4, 5 does not appear to involve Notch signalling.
Functional role of Dll1 expression/activity in human PCa cell lines
Dll1 was highly expressed in LNCaP cells, but was significantly downregulated in both PC-3 and PC-3M cell lines. Furthermore, decreasing the levels of Dll1 increased the lateral motility of PC-3 cells and, conversely, high levels of Dll1 significantly reduced motility. These findings are consistent with the hypothesis that Dll1 restricts motility, as found for keratinocytes 29 and 3T3 cells. 30 However, as conditions that altered Dll1 expression significantly did not affect Notch signalling through Hes1, Dll1 may act independently of its role as a Notch ligand, as suggested previously. 30 In addition, as gsecretase inhibition could lead to increased Dll1 expression, it is possible that an inhibitory feedback loop exists between the Notch pathway and Dll1 in the PC-3 model cells (see Figure 1) . Although not investigated here, this may occur through Hes1 and hASH1, as has been found for the equivalent homologues in foetal mouse pulmonary epithelium 26 and Drosophila. 42 Finally, although we have previously presented evidence that functional VGSCs are expressed in PC-3 cells 5 and that VGSC activity enhances lateral motility, 10 the effect of Dll1 was independent of this, at the transcriptional level and the signalling pathways through which Dll1 may act in PCa and other cell types, remains unclear.
Other aspects of Notch signalling in human PCa cell lines Notch receptors. Notch1 transcript levels were significantly higher in LNCaP but not in PC-3 or PC-3M cells, when compared to PNT2 cells. This trend is consistent with that reported by Shou et al. 17 LNCaP cells are weakly/non-metastatic, suggesting that Notch1 may not be involved in metastasis. On the other hand, Zayzafoon et al. 19 have reported that Notch1 levels in human PCa cell lines correlated positively with the osteoblastic nature of certain human PCa cell lines. We should note, however, that LNCaP cells were isolated from a nonskeletal metastasis (a lymph node metastasis; Horoszewicz et al. 34 ), and although PC-3 cells were derived from a bone marrow metastasis, they are osteolytic by nature. 43 In contrast to Notch1, little is known about Notch2 in PCa cells. We have found that Notch2 levels did not vary significantly from baseline levels in either LNCaP or PC-3 cell lines, but were significantly higher in PC-3M cells. As the PC-3M cell line is strongly metastatic, 35 Notch2 may be important in pathways active during aggressive secondary tumour formation. Notch3 and Notch4 did not show significant levels of expression and may thus not play an important role in PCa progression.
Notch ligands. Jagged1, but not Jagged2, levels were increased in all three PCa cell lines. This pattern of expression would suggest that Jagged1 may have a role in oncogenic transformation and/or in the maintenance of the neoplastic phenotype. Indeed, Jagged1 is known to play an essential role in cellular transformation 44 and, recently, Jagged1 expression has been correlated with human PCa metastasis. 19 However, our results for Jagged1 (but not Jagged2) differ from those of Shou et al., 17 who reported that Jagged1 was expressed in a normal prostate epithelial cell line (PrE), to a lesser extent in LNCaP cells and were virtually undetectable in other Voltage-gated sodium channels and notch signalling N Scorey et al (PC-3 and DU145) human PCa cells. In addition, we found that Dll1 mRNA was expressed in LNCaP cells, but downregulated in the PC-3 and PC-3M cell lines. Zayzafoon et al. 19 also found Dll1 expression in LNCaP cells but higher levels in C4-2B cells, a highly metastatic derivative of the LNCaP cell line. In contrast, Shou et al. 17 reported undetectable Dll1 levels in human PCa cells (LNCaP, PC-3 and DU145). This discrepancy could be owing to the methodological differences (e.g. the culture conditions). However, in our study, expression of Dll1 was consistent with its functional activity. Further elucidation of the exact pattern of Notch ligand expression in PCa cells in relation to metastatic potential is required, ideally using 'matched' cell lines. 45 Notch downstream targets. Following Notch receptorligand binding, two cleavage steps result in the release of an intracellular fragment, which translocates to the nucleus where it binds to a CSL protein resulting in transcriptional activation of Notch target genes including Hes1 and Deltex. The Notch downstream target Hes1, but not Deltex, was expressed in all four cell lines tested. Consistent expression of Hes1 would indicate that the Notch pathway is active in both normal and cancerous cells. Hes1 levels were significantly downegulated in the LNCaP cells, indicating that there is some loss of Notch activity in the non-metastatic cell line. This is in agreement with Zayzafoon et al., 19 who found that, in comparison to the LNCaP cell line, Hes1 expression levels were 20-fold higher in C4-2B cells, a highly metastatic derivative of the LNCaP cell line. Thus, Hes1 may function as a tumour suppressor during primary prostate tumour formation. Such a role for Hes1 has been reported previously for breast cancer. 46 In both metastatic lines, however, Hes1 transcript levels did not vary significantly from baseline levels, suggesting a possible return to 'normal' signalling levels in the advanced stages of PCa.
Independence of Notch signalling and VGSC expression/activity
Our functional (motility) studies have suggested that Notch signalling through Hes1 contributes to metastatic progression, as 20 mM DAPT (which reduced Hes1 transcript levels) significantly reduced the lateral motility of both LNCaP and PC-3 cells. However, this effect of Hes1 was independent of the VGSC as (i) TTX had no effect on Hes1 transcript levels; (ii) DAPT (which reduced Hes1 transcript levels) had no effect on Nav1.7 transcript levels and (iii) reducing both VGSC functional activity and Hes1 transcript levels together led to an additive reduction in cell motility. Although Notch signalling may be independent of VGSC expression/ activity under the conditions of the present study, we cannot rule out the possibility that Notch and VGSCs could interact under other conditions during the complex process of cancer and the metastatic cascade. For example, hypoxia, an important aspect of cancer progression, involves both Notch signalling 47 and VGSC expression/activity. 48 Furthermore, Notch activity has been shown to play a critical role during neurogenesis 49 and, hence, could be involved at an earlier stage of PCa, for example, at initiation of VGSC expression.
Concluding remarks
The central events involved in Notch signal transduction are highly conserved from Drosophila to man, but its outcome is very much dependent on cellular context, signal strength and environment. 50 In human PCa, aberrant levels of Notch signalling have been implicated previously in tumour formation. 14, 15 Our results also suggest that individual components of the Notch cascade could contribute to metastatic PCa by enhancing lateral motility, independently of one another and VGSC activity. Further work is required to determine whether Notch signalling could (i) control other components of the metastatic cascade and (ii) interact with VGSCs when the cellular environment changes during the spatially and temporally highly dynamic metastatic process. 51 
